Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new antithrombotic agents].

M Meyer Samama1

  • 1Service d'hématologie-immunologie, Hôpital Hôtel-Dieu, Paris. mmsamama@aol.com

Presse Medicale (Paris, France : 1983)
|November 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A new cause of hereditary venous thrombosis: activated protein C resistance].

Annales de cardiologie et d'angeiologie·1995
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

New antithrombotic agents target Factor Xa and Factor IIa, offering improved efficacy and safety profiles. Novel anticoagulants and antiplatelet drugs show promise for preventing and treating thrombosis.

Area of Science:

  • Pharmacology
  • Hematology
  • Vascular Medicine

Background:

  • Current antithrombotic therapies include anticoagulants (heparin, vitamin K antagonists) and antiplatelet agents (aspirin, clopidogrel).
  • Key research areas focus on specific inhibition of Factor Xa and Factor IIa (thrombin).
  • Development of novel agents aims to improve efficacy and safety in thrombosis management.

Purpose of the Study:

  • To review current and emerging antithrombotic agents.
  • To highlight advancements in anticoagulants and antiplatelet therapies.
  • To discuss the potential of new drugs targeting specific coagulation factors.

Main Methods:

  • Review of current literature on antithrombotic agents.
  • Discussion of investigational drugs targeting Factor Xa and Factor IIa.

Related Experiment Videos

  • Analysis of clinical applications and monitoring requirements for new agents.

    • Main Results:

    • Pentasaccharide (indirect anti-Xa) shows efficacy in deep vein thrombosis and prophylaxis post-orthopedic surgery without thrombocytopenia risk.
    • Direct thrombin inhibitors like melagatran offer effective anticoagulation without routine laboratory monitoring.
    • Oral prodrug ximelagatran may provide an alternative to vitamin K antagonists for long-term treatment.
    • Development of tissue factor-factor VIIa complex antagonists is ongoing.
    • Thienopyridines (clopidogrel, ticlopidine) demonstrate modest superiority over aspirin for arterial thrombosis, with aspirin plus thienopyridine validated post-coronary stent placement.

    Conclusions:

    • Novel anticoagulants targeting Factor Xa and IIa offer improved therapeutic options with potentially reduced monitoring and side effects.
    • Emerging antiplatelet strategies, particularly dual therapy with aspirin and thienopyridines, are crucial for arterial thrombosis management.
    • Further research and clinical validation are essential for the widespread adoption of these advanced antithrombotic agents.